The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

However, this came as good news for investors in AbbVie’s peer Bristol Myers Squibb (NYSE:BMY) as the company recently secured the U.S. FDA approval for its schizophrenia drug Cobenfy ...

Benefiting from the news, however, was Bristol Myers Squibb Co., which gained U.S. FDA approval in September 2024 for Cobenfy (xanomeline-trospium), a dual M1/M4 muscarinic agonist, with shares ...

Bristol Myers Squibb ($BMY) stock rocketed over 11% in early morning trading on Monday to hit a 14-month high of $61.08 after ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Bristol-Myers Squibb has also been making strides in clinical trials. Notably, the FDA approved Cobenfy, a new treatment for schizophrenia, and the company reported promising news about milvexian.

Bristol-Myers Squibb has also been making strides in clinical trials. Notably, the FDA approved Cobenfy, a new treatment for schizophrenia, and the company reported promising news about milvexian.

And Cobenfy's approval comes after two other recent setbacks in the late-stage schizophrenia pipeline; namely, the FDA’s rejection of Minerva Neurosciences’ application for roluperidone and ...